SE9402430L - Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten - Google Patents

Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten

Info

Publication number
SE9402430L
SE9402430L SE9402430A SE9402430A SE9402430L SE 9402430 L SE9402430 L SE 9402430L SE 9402430 A SE9402430 A SE 9402430A SE 9402430 A SE9402430 A SE 9402430A SE 9402430 L SE9402430 L SE 9402430L
Authority
SE
Sweden
Prior art keywords
conjugate
conjugates
peptide
targeting compound
modified superantigen
Prior art date
Application number
SE9402430A
Other languages
English (en)
Other versions
SE9402430D0 (sv
Inventor
Lars Abrahmsen
Per Bjoerk
Mikael Dohlsten
Terje Kalland
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE9402430A priority Critical patent/SE9402430L/sv
Publication of SE9402430D0 publication Critical patent/SE9402430D0/sv
Priority to ES95926057T priority patent/ES2158950T3/es
Priority to AU29940/95A priority patent/AU699147B2/en
Priority to DK95926057T priority patent/DK0766566T3/da
Priority to PL95318162A priority patent/PL180747B1/pl
Priority to AT95926057T priority patent/ATE200626T1/de
Priority to KR1019970700156A priority patent/KR100377506B1/ko
Priority to PT95926057T priority patent/PT766566E/pt
Priority to JP50425196A priority patent/JP4175489B2/ja
Priority to US08/765,695 priority patent/US7226601B1/en
Priority to HU9700063A priority patent/HU221254B1/hu
Priority to CA002194673A priority patent/CA2194673C/en
Priority to NZ289951A priority patent/NZ289951A/xx
Priority to PCT/SE1995/000681 priority patent/WO1996001650A1/en
Priority to RU97102113/13A priority patent/RU2183215C2/ru
Priority to DE69520739T priority patent/DE69520739T2/de
Priority to CN95194071A priority patent/CN1089606C/zh
Priority to HK98113340.3A priority patent/HK1012226B/en
Priority to EP95926057A priority patent/EP0766566B1/en
Priority to TW084106800A priority patent/TW413636B/zh
Priority to IL11444595A priority patent/IL114445A/xx
Priority to UA97020534A priority patent/UA73067C2/uk
Priority to MYPI95001925A priority patent/MY112916A/en
Priority to ZA955746A priority patent/ZA955746B/xx
Publication of SE9402430L publication Critical patent/SE9402430L/sv
Priority to FI970100A priority patent/FI118150B/sv
Priority to NO19970108A priority patent/NO320151B1/no
Priority to GR20010401035T priority patent/GR3036187T3/el
Priority to US11/193,748 priority patent/US20050260215A1/en
Priority to US11/193,869 priority patent/US20060062795A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SE9402430A 1994-07-11 1994-07-11 Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten SE9402430L (sv)

Priority Applications (29)

Application Number Priority Date Filing Date Title
SE9402430A SE9402430L (sv) 1994-07-11 1994-07-11 Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
HU9700063A HU221254B1 (en) 1994-07-11 1995-06-07 A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
RU97102113/13A RU2183215C2 (ru) 1994-07-11 1995-06-07 Конъюгат для стимулирования иммунной реакции против клетки-мишени, способ лечения злокачественных опухолей у млекопитающего
DE69520739T DE69520739T2 (de) 1994-07-11 1995-06-07 Konjugat aus einem modifizierten superantigen und einer zielsuchenden verbindung und die verwendung des konjugats
DK95926057T DK0766566T3 (da) 1994-07-11 1995-06-07 Konjugat mellem et modificeret superantigen og en målsøgende forbindelse samt anvendelse af konjugatet
PL95318162A PL180747B1 (pl) 1994-07-11 1995-06-07 Koniugat przeciwciało-superantygen
AT95926057T ATE200626T1 (de) 1994-07-11 1995-06-07 Konjugat aus einem modifizierten superantigen und einer zielsuchenden verbindung und die verwendung des konjugats
KR1019970700156A KR100377506B1 (ko) 1994-07-11 1995-06-07 변이된초항원과표적-탐지화합물간의복합체,이복합체를함유하는제약학적조성물및이를이용한치료방법
PT95926057T PT766566E (pt) 1994-07-11 1995-06-07 Um conjugado entre um superantigenio modificado e um composto buscador de alvos e utilizacao do conjugado
JP50425196A JP4175489B2 (ja) 1994-07-11 1995-06-07 改変型超抗原と標的探索化合物との結合体及び該結合体の使用
US08/765,695 US7226601B1 (en) 1994-07-11 1995-06-07 Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
AU29940/95A AU699147B2 (en) 1994-07-11 1995-06-07 A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
CA002194673A CA2194673C (en) 1994-07-11 1995-06-07 A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
NZ289951A NZ289951A (en) 1994-07-11 1995-06-07 A conjugate between a modified superantigen and a target seeking compound; use of the conjugate for lysis of cells
PCT/SE1995/000681 WO1996001650A1 (en) 1994-07-11 1995-06-07 A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
ES95926057T ES2158950T3 (es) 1994-07-11 1995-06-07 Un conjugado entre un superantigeno modificado y un compuesto buscador de blanco y el uso del conjugado.
HK98113340.3A HK1012226B (en) 1994-07-11 1995-06-07 A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
EP95926057A EP0766566B1 (en) 1994-07-11 1995-06-07 A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
CN95194071A CN1089606C (zh) 1994-07-11 1995-06-07 一种修饰的超抗原和一种寻找靶物化合物的缀合物和该缀合物的用途
TW084106800A TW413636B (en) 1994-07-11 1995-07-01 A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
IL11444595A IL114445A (en) 1994-07-11 1995-07-04 Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
UA97020534A UA73067C2 (en) 1994-07-11 1995-07-06 Conjugate between modified superantigene and compound directed to the target
MYPI95001925A MY112916A (en) 1994-07-11 1995-07-10 A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
ZA955746A ZA955746B (en) 1994-07-11 1995-07-11 A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
FI970100A FI118150B (sv) 1994-07-11 1997-01-10 Konjugat mellan en modifierad superantigen och målsökande förening samt användning av konjugatet
NO19970108A NO320151B1 (no) 1994-07-11 1997-01-10 Konjugat mellom en biospesifikk affinitetsmotpart og et peptid avledet fra et superantigen som er kovalent bundet til hverandre
GR20010401035T GR3036187T3 (en) 1994-07-11 2001-07-06 A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
US11/193,748 US20050260215A1 (en) 1994-07-11 2005-07-29 Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
US11/193,869 US20060062795A1 (en) 1994-07-11 2005-07-29 Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9402430A SE9402430L (sv) 1994-07-11 1994-07-11 Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten

Publications (2)

Publication Number Publication Date
SE9402430D0 SE9402430D0 (sv) 1994-07-11
SE9402430L true SE9402430L (sv) 1996-01-12

Family

ID=20394684

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9402430A SE9402430L (sv) 1994-07-11 1994-07-11 Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten

Country Status (26)

Country Link
US (3) US7226601B1 (sv)
EP (1) EP0766566B1 (sv)
JP (1) JP4175489B2 (sv)
KR (1) KR100377506B1 (sv)
CN (1) CN1089606C (sv)
AT (1) ATE200626T1 (sv)
AU (1) AU699147B2 (sv)
CA (1) CA2194673C (sv)
DE (1) DE69520739T2 (sv)
DK (1) DK0766566T3 (sv)
ES (1) ES2158950T3 (sv)
FI (1) FI118150B (sv)
GR (1) GR3036187T3 (sv)
HU (1) HU221254B1 (sv)
IL (1) IL114445A (sv)
MY (1) MY112916A (sv)
NO (1) NO320151B1 (sv)
NZ (1) NZ289951A (sv)
PL (1) PL180747B1 (sv)
PT (1) PT766566E (sv)
RU (1) RU2183215C2 (sv)
SE (1) SE9402430L (sv)
TW (1) TW413636B (sv)
UA (1) UA73067C2 (sv)
WO (1) WO1996001650A1 (sv)
ZA (1) ZA955746B (sv)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
DE69837706T2 (de) * 1997-07-21 2008-01-10 Active Biotech Ab Zytolyse der geeigneten zielzellen mit superantigen konjugate mittels der induktion von t-zell aktivierung
DE19827837A1 (de) * 1998-06-23 1999-12-30 Ernst Gleichmann Universell an Haupthistokompatibilitätskomplexmoleküle der Klasse II bindende Peptide zur prädiktiven Testung, Diagnostik, Prophylaxe und Therapie von Sensibilisierungen gegen Chemikalen
US7491402B2 (en) 1998-12-24 2009-02-17 Auckland Uniservices Limited Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0118155D0 (en) * 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
NZ519371A (en) 2002-06-04 2004-11-26 Auckland Uniservices Ltd Immunomodulatory constructs and their uses
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
JP2008520227A (ja) * 2004-11-18 2008-06-19 メディジーン リミテッド 可溶性二官能性タンパク質
KR20130108481A (ko) * 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CN102516392B (zh) * 2011-11-25 2014-05-28 孙嘉琳 一种癌靶向超抗原融合蛋白及制备方法及用途
WO2014025199A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
AU2017206656B2 (en) 2016-01-10 2024-02-01 Neotx Therapeutics Ltd. Immunopotentiator enhanced superantigen mediated cancer immunotherapy
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
EP3820467A4 (en) * 2018-07-09 2022-05-04 Synthis Therapeutics, Inc. ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
AU2020275142A1 (en) 2019-05-15 2021-12-16 Neotx Therapeutics Ltd. Cancer treatment
IL296103A (en) 2020-03-05 2022-11-01 Neotx Therapeutics Ltd Methods and compositions for treating cancer with immune cells
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627644A (en) 1968-03-01 1971-12-14 Hajime Okamoto Process for the cultivation of hemolytic streptococci
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4268434A (en) 1979-01-09 1981-05-19 Higerd Thomas B Immunosuppressive extracellular product from oral bacteria
SU1304736A3 (ru) * 1981-04-14 1987-04-15 Др.Мадаус Унд Ко (Фирма) Способ получени противоопухолевого средства
US5091091A (en) 1981-11-06 1992-02-25 Terman David S Protein A perfusion and post perfusion drug infusion
US4699783A (en) 1983-03-11 1987-10-13 Terman David S Products and methods for treatment of cancer
US4681870A (en) 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
IT1192014B (it) 1986-06-27 1988-03-31 Rubinetterie Mariani Spa Becco di erogazione per lavabo o simile apparecchio idraulico con comando del salterello
US4980160A (en) 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
ES2058538T3 (es) 1988-07-22 1994-11-01 Imre Corp Compuestos de proteina a purificados y procedimiento para su preparacion.
SE8903100D0 (sv) 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
CA2078003C (en) 1990-01-17 2006-11-21 David S. Terman Tumor killing effects of enterotoxins and related compounds
DK0610179T3 (da) * 1990-07-20 1997-03-24 Pharmacia & Upjohn Ab Målspecifikke antistof-superantigenkonjugater og fremstilling deraf
US5858363A (en) * 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
US6197299B1 (en) * 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
WO1993014634A1 (en) 1992-01-28 1993-08-05 National Jewish Center For Immunology And Respiratory Medicine Protective effects of mutated superantigens
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy

Also Published As

Publication number Publication date
PL318162A1 (en) 1997-05-26
RU2183215C2 (ru) 2002-06-10
HU221254B1 (en) 2002-09-28
NZ289951A (en) 1998-12-23
HK1012226A1 (en) 1999-07-30
UA73067C2 (en) 2005-06-15
HUT77257A (hu) 1998-03-02
IL114445A0 (en) 1995-11-27
EP0766566B1 (en) 2001-04-18
NO970108L (no) 1997-02-20
AU2994095A (en) 1996-02-09
CA2194673C (en) 2009-08-04
CA2194673A1 (en) 1996-01-25
DE69520739D1 (de) 2001-05-23
GR3036187T3 (en) 2001-10-31
SE9402430D0 (sv) 1994-07-11
FI970100L (sv) 1997-01-10
IL114445A (en) 1999-09-22
TW413636B (en) 2000-12-01
US20050260215A1 (en) 2005-11-24
PL180747B1 (pl) 2001-04-30
DK0766566T3 (da) 2001-08-13
FI970100A0 (sv) 1997-01-10
AU699147B2 (en) 1998-11-26
FI118150B (sv) 2007-07-31
WO1996001650A1 (en) 1996-01-25
ES2158950T3 (es) 2001-09-16
EP0766566A1 (en) 1997-04-09
ATE200626T1 (de) 2001-05-15
MY112916A (en) 2001-10-31
DE69520739T2 (de) 2001-09-20
CN1152877A (zh) 1997-06-25
NO970108D0 (no) 1997-01-10
KR100377506B1 (ko) 2003-06-11
NO320151B1 (no) 2005-10-31
ZA955746B (en) 1996-02-20
US7226601B1 (en) 2007-06-05
US20060062795A1 (en) 2006-03-23
CN1089606C (zh) 2002-08-28
PT766566E (pt) 2001-09-28
JP4175489B2 (ja) 2008-11-05
JPH11500407A (ja) 1999-01-12

Similar Documents

Publication Publication Date Title
SE9402430D0 (sv) Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
DE69729283D1 (de) GLYKOSYLIERTE IgG ANTIKÖRPER
NO20051048L (no) Terapeutisk humant anti-IL-1R1 monoklonalt antistoff
DE69830492D1 (de) Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME)
AU3202195A (en) Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
WO1989007269A1 (en) Method for the preparation of antibody-fragment conjugates
ATE328611T1 (de) Multiple,kohlenhydrathaltige glycopeptid-antigene,daraus entwickelte impfstoffe sowie deren verwendung
CN101132810A (zh) 含有肽聚糖的糖缀合物疫苗
RU97102113A (ru) Конъюгат между модифицированным суперантигеном и направленным к мишени соединением и применение конъюгата
EP0820469A4 (en) IDENTIFICATION, CLEANING AND USE OF LECZYMS AND CARBOHYDRATE LIGANDS
US4902495A (en) IgE Fc directed delivery system
EP0792162A4 (en) USE OF ANTIBODIES TO PREVENT EFFECTS CAUSED BY GRAMPOSITIVE AND MYKO BACTERIA
AU641736B2 (en) Delivery of agents
Givner et al. Type III group B Streptococcus: functional interaction with IgG subclass antibodies
Boquet et al. Studies on the Role of a Nucleoside‐Phosphate‐Binding Site of Diphtheria Toxin in the Binding of Toxin to Vero Cells or Liposomes
Rehlaender et al. Antibodies as drug carriers. II. For proteins
NO951061L (no) Antistoffkonjugater med forbedrede egenskaper
MX9707295A (es) Metodo para mejorar la respuesta de los anticuerpos a los antigenos especificos con interleucina-10.

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 9402430-4